Chinese biopharma 3SBio in $290 million deal for unit of Canada's Therapure: Reuters

China’s 3SBio Inc (1530.HK) has agreed to buy the contract development and manufacturing unit of Canada’s Therapure Biopharma Inc for $290 million, part of a push by the Chinese biotech company into the North American market.

DealsNorth AmericaUSBriefs